FDA approves Pfizer medication for juvenile arthritis
from The Weekly Journal
Pfizer Inc. announced that the U.S. Food and Drug Administration approved XELJANZ for the treatment of children and adolescents two years and older with active polyarticular course juvenile idiopathic arthritis.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063